Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (REFALS)
Sponsor: Orion Corporation, Orion Pharma
A PHASE3 clinical study on Amyotrophic Lateral Sclerosis, this trial is completed. The trial is conducted by Orion Corporation, Orion Pharma and has accumulated 15 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jun 2022 [monthly]
Completed PHASE3
▶ Show 10 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2019 — Nov 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2019 — Sep 2019 [monthly]
Recruiting PHASE3
-
Mar 2019 — Jun 2019 [monthly]
Recruiting PHASE3
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE3
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE3
-
Oct 2018 — Jan 2019 [monthly]
Recruiting PHASE3
-
Aug 2018 — Oct 2018 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Orion Corporation, Orion Pharma
For direct contact, visit the study record on ClinicalTrials.gov .